1
|
Kozłowska L, Santonen T, Duca RC, Godderis L, Jagiello K, Janasik B, Van Nieuwenhuyse A, Poels K, Puzyn T, Scheepers PTJ, Sijko M, Silva MJ, Sosnowska A, Viegas S, Verdonck J, Wąsowicz W. HBM4EU Chromates Study: Urinary Metabolomics Study of Workers Exposed to Hexavalent Chromium. Metabolites 2022; 12:362. [PMID: 35448548 PMCID: PMC9032989 DOI: 10.3390/metabo12040362] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 04/01/2022] [Accepted: 04/11/2022] [Indexed: 11/30/2022] Open
Abstract
Exposure to hexavalent chromium Cr(VI) may occur in several occupational activities, placing workers in many industries at risk for potential related health outcomes. Untargeted metabolomics was applied to investigate changes in metabolic pathways in response to Cr(VI) exposure. We obtained our data from a study population of 220 male workers with exposure to Cr(VI) and 102 male controls from Belgium, Finland, Poland, Portugal and the Netherlands within the HBM4EU Chromates Study. Urinary metabolite profiles were determined using liquid chromatography mass spectrometry, and differences between post-shift exposed workers and controls were analyzed using principal component analysis. Based on the first two principal components, we observed clustering by industrial chromate application, such as welding, chrome plating, and surface treatment, distinct from controls and not explained by smoking status or alcohol use. The changes in the abundancy of excreted metabolites observed in workers reflect fatty acid and monoamine neurotransmitter metabolism, oxidative modifications of amino acid residues, the excessive formation of abnormal amino acid metabolites and changes in steroid and thyrotropin-releasing hormones. The observed responses could also have resulted from work-related factors other than Cr(VI). Further targeted metabolomics studies are needed to better understand the observed modifications and further explore the suitability of urinary metabolites as early indicators of adverse effects associated with exposure to Cr(VI).
Collapse
Affiliation(s)
- Lucyna Kozłowska
- Laboratory of Human Metabolism Research, Department of Dietetics, Warsaw University of Life Sciences, 02776 Warsaw, Poland;
| | - Tiina Santonen
- Finnish Institute of Occupational Health, 00250 Helsinki, Finland;
| | - Radu Corneliu Duca
- Labotoire National de Santé (LNS), Unit Environmental Hygiene and Human Biological Monitoring, Department of Health Protection, 3555 Dudelange, Luxembourg;
- Centre for Environment and Health, Department of Public Health and Primary Care, KU Leuven (University of Leuven), 3000 Leuven, Belgium; (L.G.); (A.V.N.); (K.P.); (J.V.)
| | - Lode Godderis
- Centre for Environment and Health, Department of Public Health and Primary Care, KU Leuven (University of Leuven), 3000 Leuven, Belgium; (L.G.); (A.V.N.); (K.P.); (J.V.)
- IDEWE, External Service for Prevention and Protection at Work, 3001 Heverlee, Belgium
| | - Karolina Jagiello
- QSAR Laboratory Ltd., 80172 Gdansk, Poland; (K.J.); (T.P.); (A.S.)
- Laboratory of Environmental Chemoinfomatics, Department of Environmental Chemistry and Radiochemistry, Faculty of Chemistry, University of Gdansk, 80308 Gdansk, Poland
| | - Beata Janasik
- Department of Environmental and Biological Monitoring, Nofer Institute of Occupational Medicine, 91348 Lodz, Poland; (B.J.); (W.W.)
| | - An Van Nieuwenhuyse
- Centre for Environment and Health, Department of Public Health and Primary Care, KU Leuven (University of Leuven), 3000 Leuven, Belgium; (L.G.); (A.V.N.); (K.P.); (J.V.)
- Laboratoire National de Santé (LNS), Department of Health Protection, 3555 Dudelange, Luxembourg
| | - Katrien Poels
- Centre for Environment and Health, Department of Public Health and Primary Care, KU Leuven (University of Leuven), 3000 Leuven, Belgium; (L.G.); (A.V.N.); (K.P.); (J.V.)
| | - Tomasz Puzyn
- QSAR Laboratory Ltd., 80172 Gdansk, Poland; (K.J.); (T.P.); (A.S.)
- Laboratory of Environmental Chemoinfomatics, Department of Environmental Chemistry and Radiochemistry, Faculty of Chemistry, University of Gdansk, 80308 Gdansk, Poland
| | - Paul T. J. Scheepers
- Radboud Institute for Health Sciences, Radboudumc, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands;
| | - Monika Sijko
- Laboratory of Human Metabolism Research, Department of Dietetics, Warsaw University of Life Sciences, 02776 Warsaw, Poland;
| | - Maria João Silva
- Human Genetics Department, National Institute of Health Dr. Ricardo Jorge (INSA), Toxicogenomics and Human Health (ToxOmics), NOVA Medical School, Universidade Nova de Lisboa, 1169-056 Lisbon, Portugal;
| | - Anita Sosnowska
- QSAR Laboratory Ltd., 80172 Gdansk, Poland; (K.J.); (T.P.); (A.S.)
| | - Susana Viegas
- Public Health Research Centre, NOVA National School of Public Health, Universidade NOVA de Lisbon, 1600-560 Lisbon, Portugal;
- Comprehensive Health Research Center (CHRC), 1169-056 Lisbon, Portugal
| | - Jelle Verdonck
- Centre for Environment and Health, Department of Public Health and Primary Care, KU Leuven (University of Leuven), 3000 Leuven, Belgium; (L.G.); (A.V.N.); (K.P.); (J.V.)
| | - Wojciech Wąsowicz
- Department of Environmental and Biological Monitoring, Nofer Institute of Occupational Medicine, 91348 Lodz, Poland; (B.J.); (W.W.)
| | | | | |
Collapse
|
3
|
Haus E. Chronobiology in the endocrine system. Adv Drug Deliv Rev 2007; 59:985-1014. [PMID: 17804113 DOI: 10.1016/j.addr.2007.01.001] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2006] [Accepted: 01/15/2007] [Indexed: 12/13/2022]
Abstract
Biological signaling occurs in a complex web with participation and interaction of the central nervous system, the autonomous nervous system, the endocrine glands, peripheral endocrine tissues including the intestinal tract and adipose tissue, and the immune system. All of these show an intricate time structure with rhythms and pulsatile variations in multiple frequencies. Circadian (about 24-hour) and circannual (about 1-year) rhythms are kept in step with the cyclic environmental surrounding by the timing and length of the daily light span. Rhythmicity of many endocrine variables is essential for their efficacy and, even in some instances, for the qualitative nature of their effects. Indeed, the continuous administration of certain hormones and their synthetic analogues may show substantially different effects than expected. In the design of drug-delivery systems and treatment schedules involving directly or indirectly the endocrine system, consideration of the human time organization is essential. A large amount of information on the endocrine time structure has accumulated, some of which is discussed in this review.
Collapse
Affiliation(s)
- Erhard Haus
- Department of Laboratory Medicine and Pathology, University of Minnesota, Health Partners Medical Group, Regions Hospital, 640 Jackson Street, St. Paul, Minnesota 55101, USA.
| |
Collapse
|
4
|
Nie Y, Schoepp DD, Klaunig JE, Yard M, Lahiri DK, Kubek MJ. Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. Brain Res 2005; 1054:45-54. [PMID: 16055093 DOI: 10.1016/j.brainres.2005.06.077] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2005] [Revised: 06/17/2005] [Accepted: 06/25/2005] [Indexed: 10/25/2022]
Abstract
Excess excitatory amino acid release is involved in pathways associated with seizures and neurodegeneration. Thyrotropin-releasing hormone (TRH; protirelin), a brain-derived tripeptide, has shown efficacy in the treatment of such disorders, yet its mechanism of neuroprotection is poorly understood. Using superfused hippocampal slices, we tested the hypothesis that TRH could inhibit evoked glutamate/aspartate release in vitro. Rat hippocampal slices were first equilibrated in oxygenated Krebs buffer (KRB) (120 min) then superfused for 10 min with KRB (control), or KRB containing 0.1, 1, or 10 microM TRH respectively, prior to and during 5 min depolarization with high potassium KRB (50 mM [K(+)] +/- TRH). Fractions (1 min) were collected during the 5 min stimulation and for an additional 10 min thereafter and analyzed for glutamate and aspartate by HPLC. TRH had no effect on baseline glutamate/aspartate release, while all three TRH doses significantly (P < 0.05) inhibited peak 50 mM [K(+)]-stimulated glutamate/aspartate release, and glutamate remained below control (P < 0.05) at 15 min post stimulation. A 5 min pulse of TRH (10 microM) had no affect on basal glutamate/aspartate release, whereas the TRH pre-pulsed slices failed to release glutamate/aspartate by [K(+)]-stimulation given 15 min later. These results are the first to show a potent and prolonged inhibitory effect of TRH on evoked glutamate/aspartate release in vitro. These initial studies suggest that exogenous and/or endogenous TRH may function, in part, to modulate excess glutamate release in specific CNS loci. Additional studies are in progress to fully understand the mechanism of this potent effect of TRH and its implication in various CNS disorders.
Collapse
Affiliation(s)
- Y Nie
- Department of Anatomy and Cell Biology, MS 5035, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202, USA
| | | | | | | | | | | |
Collapse
|
5
|
Abstract
Cocaine administration has previously been reported to alter the levels of prepro-TRH mRNA and TRH (pGlu-His-Pro-NH(2)) in the limbic system of rats (J. Neurochem. 60 (1993) 1151). We have now demonstrated that a previously unrecognized family of TRH-like peptides is involved in the actions of cocaine. We treated young adult male Sprague-Dawley rats (five per group, 250g body weight at sacrifice) for 2 weeks with either twice daily injections of saline (control group), twice daily injections of 15mg/kg cocaine until sacrifice (chronic group), single injection of 15mg/kg cocaine 2h prior to sacrifice (acute group) or chronic cocaine injections replaced by saline injections 72h prior to sacrifice (withdrawal group (WD)). Twelve different brain regions were dissected and immunoreactivity for TRH (TRH-IR), EEP (pGlu-Glu-Pro-NH(2); EEP-IR) and related peptides were measured by radioimmunoassay (RIA). High pressure liquid chromatography (HPLC) revealed that in many brain regions EEP-IR and TRH-IR consisted of a mixture of TRH, and other TRH-like peptides including EEP, pGlu-Val-Pro-NH(2) (Val(2)-TRH), pGlu-Tyr-Pro-NH(2) (Tyr(2)-TRH), pGlu-Leu-Pro-NH(2) (Leu(2)-TRH), and pGlu-Phe-Pro-NH(2) (Phe(2)-TRH). Following i.p. injection, these TRH-like peptides readily crossed the blood-brain barrier but cleared very slowly from brain tissues. Acute cocaine produced a 4.1-fold increase in Val(2)-TRH level in medulla while Val(2)-TRH and Tyr(2)-TRH, increased 6.2- and 2.9-fold, respectively in pyriform cortex PYR. TRH and Leu(2)-TRH, decreased 47 and 93%, respectively in the nucleus accumbens (AM) while other EEP-IR peaks decreased 50-100% consistent with the significant decrease in total EEP-IR in the AMs following acute cocaine treatment. Because 2h is too short a time to alter levels of neuropeptides via changes in the rate of biosynthesis, the acute cocaine-induced elevation or reduction in TRH and related peptides is most likely due to suppression or stimulation, respectively, of the corresponding peptide secretion rate. Because TRH and TRH-like peptides have antidepressant, analeptic and euphorigenic properties, we conclude that these endogenous substances are potential mediators of both the cocaine "high" and withdrawal symptoms.
Collapse
Affiliation(s)
- A Eugene Pekary
- Research Services, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
| | | | | |
Collapse
|
6
|
Abstract
Intractable seizures remain a significant therapeutic challenge despite current advances in the treatment of epilepsy. Thyrotropin-releasing hormone, the first neuroendocrine releasing factor to be isolated and fully characterized, was also the first releasing factor investigated as a possible neurotransmitter/neuromodulator outside the hypothalamus. Basic and clinical research has revealed a distinct neuroanatomic distribution and a neurochemical role for thyrotropin-releasing hormone in seizure modulation. Thyrotropin-releasing hormone and selected analogs were reported to have antiepileptic effects in several animal seizure paradigms, including kindling and electroconvulsive shock. Clinically, thyrotropin-releasing hormone treatment has been reported to be efficacious in such intractable epilepsies as infantile spasms, Lennox-Gastaut syndrome, myoclonic seizures, and other generalized and refractory partial seizures. Herein, we review evidence that suggests that thyrotropin-releasing hormone and selected thyrotropin-releasing hormone analogs may represent a new class of novel antiepileptic drugs, namely, antiepileptic neuropeptides and provide insights into potential new treatments for the intractable epilepsies.
Collapse
Affiliation(s)
- Michael J Kubek
- Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202-5120, USA
| | | |
Collapse
|
7
|
Abstract
Recent evidence indicates that, in addition to the involvement of cholinergic and other neurotransmitter systems, various neuropeptides that occur in cortical and subcortical brain regions have a role in cognitive behavior. This evidence results largely from behavioral studies in rodents and other animals, following peptide administration and only in a very few cases from similar studies in human subjects. Several neuropeptides studied appear to enhance or produce changes conducive to improvement in cognitive performance and these include vasopressin, corticotrophin-releasing hormone (CRH), somatostatin, substance P, neuropeptide Y, and thyrotrophin-releasing hormone (TRH), while one peptide, galanin, has been reported to inhibit cognitive processes. Of those neuropeptides that improve performance, only TRH has been shown recently to attenuate the memory impairment of human subjects and Alzheimer patients treated with an anticholinergic drug, and this review describes a series of complimentary studies in adult and aged rodents that contribute to our understanding of the possible mechanisms involved in the role of TRH in cognition.
Collapse
Affiliation(s)
- G W Bennett
- Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham, United Kingdom
| | | | | | | |
Collapse
|
9
|
Deshpande SB, Warnick JE. Analogs of thyrotropin-releasing hormone in potentiating the spinal monosynaptic reflex in vitro. Eur J Pharmacol 1994; 271:439-44. [PMID: 7705444 DOI: 10.1016/0014-2999(94)90804-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The efficacy of thyrotropin-releasing hormone (TRH) and its analogs to potentiate the spinal monosynaptic reflex was studied in isolated cords. The analogs examined were L-pyro-2-aminoadipyl-histidyl-thizolidine-4-carboxyamide (MK-771); pyroglutamyl-histidyl-prolineamide (TRH); pyroglutamyl-L-histidyl-3,3'-dimethyl-prolineamide (RX77368); (3-methyl-His2)TRH(methyl-TRH); gamma-buturolactone-gamma-carbonyl-histidyl-prolineamide citrate (DN-1417); pyroglutamyl-histidyl-proline (TRH-free acid); and histidyl-proline-diketopiperazine (cyclo(His-Pro)). The TRH analogs potentiated the monosynaptic reflex in a dose-dependent manner and the maximal potentiation occurred at about 1 microM. TRH-free acid potentiated the monosynaptic reflex but the maximal potentiation occurred at 100 times the TRH concentration. Cyclo(His-Pro) was totally ineffective. The concentration required to potentiate the monosynaptic reflex by 50% of the maximal response (EC50) was taken as an index for comparing various analogs in relation to TRH. The EC50 values of the analogs did not differ significantly from each other. However, the ratio of the mean value of an analog to that of TRH was of the following order: MK-771 (N- and C-terminally altered) > or = TRH > or = DN-1417 (N-terminal) > or = methyl-TRH > or = RX77368 (C-terminal) >>> TRH-free acid. Cyclo(His-Pro) was ineffective.
Collapse
Affiliation(s)
- S B Deshpande
- Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201
| | | |
Collapse
|
10
|
Watson CD, Hewitt MJ, Fone KC, Dickinson SL, Bennett GW. Behavioural effects of scopolamine and the TRH analogue RX77368 on radial arm maze performance in the rat. J Psychopharmacol 1994; 8:88-93. [PMID: 22298534 DOI: 10.1177/026988119400800203] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Effects of repeated intracerebroventricular administration of the thyrotrophin-releasing hormone (TRH) analogue, RX77368 (3,3'-dimethyl-TRH, 2 μg, once daily), on a scopolamine-induced performance deficit in an eight-arm radial maze were evaluated in adult rats. Scopolamine (0.3 mg/kg i.p.-30 min) pre-treatment produced a significant deficit in the number of unrepeated arm entries and total arm entries and increased the percentage of incorrect arm entries and the total time on the maze, compared with saline-treated controls. Prior treatment with RX77368 (40 min before maze testing) produced a partial but significant attenuation of the scopolamine-induced performance deficit on the maze during the first five trials but RX77368 also enhanced maze performance during the same period when given alone. These results suggest that the observed scopolamine-induced performance deficit on the radial arm maze partly results from a reduction in locomotion and maze exploration rather than solely impairment of memory, and that RX77368 treatment may improve radial maze performance by increasing arousal and exploratory behaviour in rats rather than directly enhancing cognition.
Collapse
Affiliation(s)
- C D Watson
- Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham University, Nottingham NG7 2UH
| | | | | | | | | |
Collapse
|
11
|
Fone KC, Johnson JV, Putland AP, Bennett GW. Ventral horn neuropeptides modulate the release of noradrenaline from tissue slices of rat brainstem and ventral thoracic spinal cord. J Neurochem 1991; 57:845-51. [PMID: 1677677 DOI: 10.1111/j.1471-4159.1991.tb08228.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The release of endogenous noradrenaline (NA) from slices of adult rat brainstem and ventral thoracic spinal cord was investigated using a fixed-volume incubation technique and HPLC with electrochemical detection. Incubation with potassium (15-50 mM) produced a dose-related increase in basal NA release that was calcium dependent. The potassium-evoked release of NA from spinal cord or brainstem slices was potentiated according to dose by preincubation with either (a) the selective alpha 2-adrenoceptor antagonist idazoxan (10(-6)-10(-4) M) or (b) the thyrotrophin-releasing hormone (TRH) analogue RX 77368 (pGlu-His-3,3'-dimethyl ProNH2; 10(-5) and 10(-4) M). Incubation of spinal cord slices with the NA uptake inhibitor maprotiline (1 microM) enhanced the effect of idazoxan but inhibited that of RX 77368. The effects of RX 77368 and potassium alone (15 mM) on NA release from both spinal cord and brainstem slices were reduced to basal levels with tetrodotoxin (10(-7) M). Similarly, preincubation of spinal cord, but not brainstem, slices with the insect neuropeptide proctolin (10(-4) M) significantly attenuated the potassium- or RX 77368-induced release of NA, whereas substance P (3 X 10(-5) and 1 X 10(-4) M) had no effect on either tissue. These results suggest that changes in NA release in the spinal cord and brainstem may mediate some of the actions of neuropeptides in ventral spinal cord, although the peptides may not be acting directly on the noradrenergic nerve terminals in these tissues.
Collapse
Affiliation(s)
- K C Fone
- Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham, England
| | | | | | | |
Collapse
|